Cover Image
市場調查報告書

黑色素瘤:開發平台分析

Melanoma - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232839
出版日期 內容資訊 英文 1779 Pages
訂單完成後即時交付
價格
Back to Top
黑色素瘤:開發平台分析 Melanoma - Pipeline Review, H1 2017
出版日期: 2017年06月30日 內容資訊: 英文 1779 Pages
簡介

所謂黑色素瘤,是黑色素細胞惡性轉換發展成腫瘤。這些細胞是來自神經嵴,黑色素瘤通常出現在皮膚上,不過是在神經嵴移行的地方譬如消化管和腦發生。女性比男性好發,尤其出現在女性的腳和男性的背部。皮膚上如果有是黑痣,痛的地方、塊、傷、花樣等明顯看到或感覺到的地方為黑色素瘤的前兆。治療方法有手術和放射線及質子治療等。

本報告提供黑色素瘤的治療藥開發平台的現狀及最新更新的各開發階段比較分析、企業和研究機關開發中的治療藥、治療藥的評估、後期階段及中止的計劃相關資訊等最新的新聞和發表。

簡介

  • 黑色素瘤 概要

治療藥的開發

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

企業開發中的產品

大學/機關研究中的產品

開發治療藥的企業

治療藥的評估

藥物簡介

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9479IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H1 2017, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 20, 105, 120, 7, 214, 29 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 14, 13, 1, 62 and 14 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Melanoma - Overview
  • Melanoma - Therapeutics Development
  • Melanoma - Therapeutics Assessment
  • Melanoma - Companies Involved in Therapeutics Development
  • Melanoma - Drug Profiles
  • Melanoma - Dormant Projects
  • Melanoma - Discontinued Products
  • Melanoma - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Melanoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..10), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..11), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..12), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..13), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..14), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..15), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..16), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..17), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..18), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..19), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..20), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..21), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..22), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..23), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..24), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..25), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..26), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..4), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..10), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..11), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..12), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..6), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..7), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..8), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..9), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..10), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..11), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017 (Contd..1), H1 2017
  • Melanoma - Pipeline by 4P-Pharma SAS, H1 2017
  • Melanoma - Pipeline by 4SC AG, H1 2017
  • Melanoma - Pipeline by AB Science SA, H1 2017
  • Melanoma - Pipeline by AbbVie Inc, H1 2017
  • Melanoma - Pipeline by Abivax SA, H1 2017
  • Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2017
  • Melanoma - Pipeline by Aduro BioTech Inc, H1 2017
  • Melanoma - Pipeline by Advanced Cancer Therapeutics LLC, H1 2017
  • Melanoma - Pipeline by Affichem SA, H1 2017
  • Melanoma - Pipeline by Agenus Inc, H1 2017
  • Melanoma - Pipeline by AGV Discovery SAS, H1 2017
  • Melanoma - Pipeline by AIMM Therapeutics BV, H1 2017
  • Melanoma - Pipeline by Alethia Biotherapeutics Inc, H1 2017
  • Melanoma - Pipeline by Alkermes Plc, H1 2017
  • Melanoma - Pipeline by Altor BioScience Corp, H1 2017
  • Melanoma - Pipeline by Amgen Inc, H1 2017
  • Melanoma - Pipeline by Anavex Life Sciences Corp, H1 2017
  • Melanoma - Pipeline by Angimmune LLC, H1 2017
  • Melanoma - Pipeline by Antibe Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Antigen Express Inc, H1 2017
  • Melanoma - Pipeline by APEIRON Biologics AG, H1 2017
  • Melanoma - Pipeline by Apexigen Inc, H1 2017
  • Melanoma - Pipeline by Aphios Corp, H1 2017
  • Melanoma - Pipeline by Apogenix GmbH, H1 2017
  • Melanoma - Pipeline by Aposense Ltd, H1 2017
  • Melanoma - Pipeline by Aptose Biosciences Inc, H1 2017
  • Melanoma - Pipeline by ARMO Biosciences Inc, H1 2017
  • Melanoma - Pipeline by Array BioPharma Inc, H1 2017
  • Melanoma - Pipeline by Asana BioSciences LLC, H1 2017
  • Melanoma - Pipeline by Astellas Pharma Inc, H1 2017
  • Melanoma - Pipeline by Astex Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by AstraZeneca Plc, H1 2017
  • Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2017
  • Melanoma - Pipeline by Autotelic Inc, H1 2017
  • Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H1 2017
  • Melanoma - Pipeline by Batu Biologics Inc, H1 2017
  • Melanoma - Pipeline by Bayer AG, H1 2017
  • Melanoma - Pipeline by BeiGene (Beijing) Co Ltd, H1 2017
  • Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2017
  • Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by BerGenBio ASA, H1 2017
  • Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2017
  • Melanoma - Pipeline by Biocad, H1 2017
  • Melanoma - Pipeline by Biogazelle NV, H1 2017
  • Melanoma - Pipeline by BioLineRx Ltd, H1 2017
  • Melanoma - Pipeline by Bioncotech Therapeutics SL, H1 2017
  • Melanoma - Pipeline by Bionomics Ltd, H1 2017
  • Melanoma - Pipeline by BioNTech AG, H1 2017
  • Melanoma - Pipeline by Biothera Pharmaceutical Inc, H1 2017
  • Melanoma - Pipeline by Biovista Inc, H1 2017
  • Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Melanoma - Pipeline by Boston Biomedical Inc, H1 2017
  • Melanoma - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Melanoma - Pipeline by Calithera Biosciences Inc, H1 2017
  • Melanoma - Pipeline by Can-Fite BioPharma Ltd, H1 2017
  • Melanoma - Pipeline by CCRP Therapeutics GmbH, H1 2017
  • Melanoma - Pipeline by Celgene Corp, H1 2017
  • Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Celprogen Inc, H1 2017
  • Melanoma - Pipeline by Celyad SA, H1 2017
  • Melanoma - Pipeline by Checkmate Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Chipscreen Biosciences Ltd, H1 2017
  • Melanoma - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
  • Melanoma - Pipeline by Cipher Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Corvus Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by CytomX Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Cytori Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Cytune Pharma SAS, H1 2017
  • Melanoma - Pipeline by CyTuVax BV, H1 2017
  • Melanoma - Pipeline by CZ BioMed Corp, H1 2017
  • Melanoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Melanoma - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Melanoma - Pipeline by DEKK-TEC Inc, H1 2017
  • Melanoma - Pipeline by Dicerna Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Dynavax Technologies Corp, H1 2017
  • Melanoma - Pipeline by Eisai Co Ltd, H1 2017
  • Melanoma - Pipeline by Eli Lilly and Company, H1 2017
  • Melanoma - Pipeline by Elsalys Biotech SAS, H1 2017
  • Melanoma - Pipeline by Ensol Biosciences Inc, H1 2017
  • Melanoma - Pipeline by EntreChem SL, H1 2017
  • Melanoma - Pipeline by eTheRNA Immunotherapies NV, H1 2017
  • Melanoma - Pipeline by Exelixis Inc, H1 2017
  • Melanoma - Pipeline by Exicure Inc, H1 2017
  • Melanoma - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
  • Melanoma - Pipeline by Faron Pharmaceuticals Oy, H1 2017
  • Melanoma - Pipeline by Galapagos NV, H1 2017
  • Melanoma - Pipeline by Galectin Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Genelux Corp, H1 2017
  • Melanoma - Pipeline by Genocea Biosciences Inc, H1 2017
  • Melanoma - Pipeline by Genzyme Corp, H1 2017
  • Melanoma - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Melanoma - Pipeline by Gradalis Inc, H1 2017
  • Melanoma - Pipeline by GreenPeptide Co Ltd, H1 2017
  • Melanoma - Pipeline by Hadasit Medical Research Services & Development Ltd, H1 2017
  • Melanoma - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017
  • Melanoma - Pipeline by Heat Biologics Inc, H1 2017
  • Melanoma - Pipeline by Hemispherx Biopharma Inc, H1 2017
  • Melanoma - Pipeline by Histogen Inc, H1 2017
  • Melanoma - Pipeline by HitGen LTD, H1 2017
  • Melanoma - Pipeline by Horizon Pharma Plc, H1 2017
  • Melanoma - Pipeline by Humorigin Biotechnology Corp, H1 2017
  • Melanoma - Pipeline by Idera Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Ignyta Inc, H1 2017
  • Melanoma - Pipeline by Immodulon Therapeutics Ltd, H1 2017
  • Melanoma - Pipeline by Immune Design Corp, H1 2017
  • Melanoma - Pipeline by Immune Response BioPharma Inc, H1 2017
  • Melanoma - Pipeline by ImmunGene Inc, H1 2017
  • Melanoma - Pipeline by Immunocore Ltd, H1 2017
  • Melanoma - Pipeline by ImmunoGen Inc, H1 2017
  • Melanoma - Pipeline by Immupharma Plc, H1 2017
  • Melanoma - Pipeline by IMPACT Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Imugene Ltd, H1 2017
  • Melanoma - Pipeline by Incyte Corp, H1 2017
  • Melanoma - Pipeline by Infinity Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Innovation Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by InteRNA Technologies BV, H1 2017
  • Melanoma - Pipeline by Intezyne Technologies Inc, H1 2017
  • Melanoma - Pipeline by IO Biotech ApS, H1 2017
  • Melanoma - Pipeline by JHL Biotech Inc, H1 2017
  • Melanoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2017
  • Melanoma - Pipeline by Johnson & Johnson, H1 2017
  • Melanoma - Pipeline by K-Stemcell Co Ltd, H1 2017
  • Melanoma - Pipeline by KaloBios Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Kancera AB, H1 2017
  • Melanoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Kite Pharma Inc, H1 2017
  • Melanoma - Pipeline by Leap Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Lentigen Technology Inc, H1 2017
  • Melanoma - Pipeline by Lindis Biotech GmbH, H1 2017
  • Melanoma - Pipeline by Lion Biotechnologies Inc, H1 2017
  • Melanoma - Pipeline by Lipotek Pty Ltd, H1 2017
  • Melanoma - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017
  • Melanoma - Pipeline by Loxo Oncology Inc, H1 2017
  • Melanoma - Pipeline by Lupin Ltd, H1 2017
  • Melanoma - Pipeline by Lytix Biopharma AS, H1 2017
  • Melanoma - Pipeline by MabVax Therapeutics Holdings Inc, H1 2017
  • Melanoma - Pipeline by MacroGenics Inc, H1 2017
  • Melanoma - Pipeline by Magnus Life Ltd, H1 2017
  • Melanoma - Pipeline by MaxiVAX SA, H1 2017
  • Melanoma - Pipeline by MediaPharma Srl, H1 2017
  • Melanoma - Pipeline by Medicenna Therapeutics Corp, H1 2017
  • Melanoma - Pipeline by MedImmune LLC, H1 2017
  • Melanoma - Pipeline by MELEMA Pharma GmbH, H1 2017
  • Melanoma - Pipeline by Merck & Co Inc, H1 2017
  • Melanoma - Pipeline by Merck KGaA, H1 2017
  • Melanoma - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Molecular Templates Inc, H1 2017
  • Melanoma - Pipeline by Moleculin Biotech Inc, H1 2017
  • Melanoma - Pipeline by Morphotek Inc, H1 2017
  • Melanoma - Pipeline by NantKwest Inc, H1 2017
  • Melanoma - Pipeline by Nektar Therapeutics, H1 2017
  • Melanoma - Pipeline by Neonc Technologies Inc, H1 2017
  • Melanoma - Pipeline by Nerviano Medical Sciences Srl, H1 2017
  • Melanoma - Pipeline by Neumedicines Inc, H1 2017
  • Melanoma - Pipeline by NewLink Genetics Corp, H1 2017
  • Melanoma - Pipeline by NormOxys Inc, H1 2017
  • Melanoma - Pipeline by Northwest Biotherapeutics Inc, H1 2017
  • Melanoma - Pipeline by Novartis AG, H1 2017
  • Melanoma - Pipeline by Novogen Ltd, H1 2017
  • Melanoma - Pipeline by Omeros Corp, H1 2017
  • Melanoma - Pipeline by Oncology Research International Ltd, H1 2017
  • Melanoma - Pipeline by Oncolys BioPharma Inc, H1 2017
  • Melanoma - Pipeline by Oncolytics Biotech Inc, H1 2017
  • Melanoma - Pipeline by OncoNOx ApS, H1 2017
  • Melanoma - Pipeline by OncoSec Medical Inc, H1 2017
  • Melanoma - Pipeline by OncoTartis Inc, H1 2017
  • Melanoma - Pipeline by Oncovir Inc, H1 2017
  • Melanoma - Pipeline by Onxeo SA, H1 2017
  • Melanoma - Pipeline by Opsona Therapeutics Ltd, H1 2017
  • Melanoma - Pipeline by Orega Biotech SAS, H1 2017
  • Melanoma - Pipeline by OSE Immunotherapeutics, H1 2017
  • Melanoma - Pipeline by Pacific Northwest Biotechnology LLC, H1 2017
  • Melanoma - Pipeline by Patrys Ltd, H1 2017
  • Melanoma - Pipeline by PepVax Inc, H1 2017
  • Melanoma - Pipeline by Peregrine Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Pfizer Inc, H1 2017
  • Melanoma - Pipeline by Pharmicell Co Ltd, H1 2017
  • Melanoma - Pipeline by Pharminox Ltd, H1 2017
  • Melanoma - Pipeline by Pharmis Biofarmaceutica Lda, H1 2017
  • Melanoma - Pipeline by Philogen SpA, H1 2017
  • Melanoma - Pipeline by PinCell srl, H1 2017
  • Melanoma - Pipeline by Pivotal BioSciences Inc, H1 2017
  • Melanoma - Pipeline by Plexxikon Inc, H1 2017
  • Melanoma - Pipeline by Polaris Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Polyplus-Transfection SA, H1 2017
  • Melanoma - Pipeline by Prima BioMed Ltd, H1 2017
  • Melanoma - Pipeline by Primevax Immuno Oncology Inc, H1 2017
  • Melanoma - Pipeline by Propanac Biopharma Inc, H1 2017
  • Melanoma - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Provenance Biopharmaceuticals Corp, H1 2017
  • Melanoma - Pipeline by Qu Biologics Inc, H1 2017
  • Melanoma - Pipeline by Rafael Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Reata Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Recepta Biopharma SA, H1 2017
  • Melanoma - Pipeline by Recombio SL, H1 2017
  • Melanoma - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Rexahn Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Rgenix Inc, H1 2017
  • Melanoma - Pipeline by Rubicon Biotechnology Inc, H1 2017
  • Melanoma - Pipeline by RXi Pharmaceuticals Corp, H1 2017
  • Melanoma - Pipeline by Sanofi, H1 2017
  • Melanoma - Pipeline by SATT North SAS, H1 2017
  • Melanoma - Pipeline by Scancell Holdings Plc, H1 2017
  • Melanoma - Pipeline by SilaGene Inc, H1 2017
  • Melanoma - Pipeline by Sillajen Biotherapeutics, H1 2017
  • Melanoma - Pipeline by SolaranRx Inc, H1 2017
  • Melanoma - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Melanoma - Pipeline by Spotlight Innovation Inc, H1 2017
  • Melanoma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
  • Melanoma - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Melanoma - Pipeline by Susavion Biosciences Inc, H1 2017
  • Melanoma - Pipeline by SuviCa Inc, H1 2017
  • Melanoma - Pipeline by Syndax Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Synthon Holdings BV, H1 2017
  • Melanoma - Pipeline by Syntrix Biosystems Inc, H1 2017
  • Melanoma - Pipeline by Tactiva Therapeutics LLC, H1 2017
  • Melanoma - Pipeline by Taiga Biotechnologies Inc, H1 2017
  • Melanoma - Pipeline by Taiwan Liposome Company Ltd, H1 2017
  • Melanoma - Pipeline by Takara Bio Inc, H1 2017
  • Melanoma - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Melanoma - Pipeline by Takis Srl, H1 2017
  • Melanoma - Pipeline by Targovax ASA, H1 2017
  • Melanoma - Pipeline by TC BioPharm Ltd, H1 2017
  • Melanoma - Pipeline by Theravectys SA, H1 2017
  • Melanoma - Pipeline by Tikcro Technologies Ltd, H1 2017
  • Melanoma - Pipeline by TILT Biotherapeutics Ltd, H1 2017
  • Melanoma - Pipeline by Tiltan Pharma Ltd, H1 2017
  • Melanoma - Pipeline by Tocagen Inc, H1 2017
  • Melanoma - Pipeline by TREAT U SA, H1 2017
  • Melanoma - Pipeline by TVAX Biomedical Inc, H1 2017
  • Melanoma - Pipeline by UbiVac LLC, H1 2017
  • Melanoma - Pipeline by Ultimovacs AS, H1 2017
  • Melanoma - Pipeline by UNC Health Care, H1 2017
  • Melanoma - Pipeline by Vaccibody AS, H1 2017
  • Melanoma - Pipeline by Vascular Biogenics Ltd, H1 2017
  • Melanoma - Pipeline by Vault Pharma Inc, H1 2017
  • Melanoma - Pipeline by Vaxenta Biotechnologies, H1 2017
  • Melanoma - Pipeline by Vichem Chemie Research Ltd, H1 2017
  • Melanoma - Pipeline by ViiV Healthcare Ltd, H1 2017
  • Melanoma - Pipeline by Viralytics Ltd, H1 2017
  • Melanoma - Pipeline by ViraTherapeutics GmbH, H1 2017
  • Melanoma - Pipeline by VLP Therapeutics LLC, H1 2017
  • Melanoma - Pipeline by WntResearch AB, H1 2017
  • Melanoma - Pipeline by X4 Pharmaceuticals Inc, H1 2017
  • Melanoma - Pipeline by Zestagen SA, H1 2017
  • Melanoma - Dormant Projects, H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..4), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..5), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..6), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..7), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..8), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..9), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..10), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..11), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..12), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..13), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..14), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..15), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..16), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..17), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..18), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..19), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..20), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..21), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..22), H1 2017
  • Melanoma - Dormant Projects, H1 2017 (Contd..23), H1 2017
  • Melanoma - Discontinued Products, H1 2017
  • Melanoma - Discontinued Products, H1 2017 (Contd..1), H1 2017
  • Melanoma - Discontinued Products, H1 2017 (Contd..2), H1 2017
  • Melanoma - Discontinued Products, H1 2017 (Contd..3), H1 2017

List of Figures

  • Number of Products under Development for Melanoma, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top